Round Table: Discussion of Regulatory Considerations for Genetically Engineered iPSC-derived Cell Therapies
Time: 1:30 pm
day: Day 2 Tracks 2 PM Clarice
Details:
- CMC characterization and reagent quality
- Balancing the regulatory approach for platform product manufacture and uniqueness of engineered cellular therapy
- Regulatory challenges to clinical entry for genetically engineered iPSC-derived cell therapies
